BIO-RESORT, presented at TCT today during a late-breaking trial session, has found no significant differences at one year between Medtronic’s Resolute Integrity (a durable polymer drug-eluting stent) and Boston Scientific’s Synergy and Biotronik’s Orsiro (both biodegradable polymer drug-eluting stents).
In this all-comers analysis, the primary composite endpoint of target vessel failure at one-year was 5.4% with Resolute Integrity, 4.7% with Synergy, and 4.7% with Orsiro. Additionally, there were no significant differences between stents in terms of stent thrombosis.
Although both Orsiro and Synergy have a biodegradable polymer, they elute different drugs – sirolimus and everolimus, respectively. Resolute Integrity elutes zotarolimus. All three devices have thin struts. Study authors Clemens (University of Twente, The Netherlands) and others report in The Lancet (The publication of BIO-RESORT in the journal coincided with the TCT presentation): “Neither of these [biodegradable] stents have [previously] been compared with the new-generation thin-strut durable polymer zotarolimus-eluting stent.”
von Birgelen, who presented the study at TCT, commented: “The BIO-RESORT trial demonstrates the continued value of high-quality randomised drug-eluting stent trials in true all-comers, reflecting real world clinical practice. BIO-RESORT included the greatest proportion of patients with ST-segment elevation myocardial infarction (STEMI) – more than 30% – of all previous randomised stent trial in all-comers and one of the greatest proportions of patients with acute coronary syndromes at almost 70%.”
He added that the long-term results of the BIO-RESORT trial “will be of great interest,” explaining that five-year follow-up of the study is planned.
